Metformin and Micronutrient Status in Type 2 Diabetes: Does Polypharmacy Involving Acid-Suppressing Medications Affect Vitamin B12 Levels?

References

• American Diabetes Association. Economic costs of diabetes in the US in 2012. Diabetes Care. 2013;36(4):1033–1046. doi:10.2337/dc12-2625
   PubMed Web of Science ®Google Scholar
• Sharma M, Nazareth I, Petersen I. Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study. BMJ Open. 2016;6(1):e010210. doi:10.1136/bmjopen-2015-010210
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Ferrannini E, Groop L, et al. T2DM mellitus. Nat Rev Dis Primers. 2015;1:15019.
   PubMed Web of Science ®Google Scholar
• Girach A, Julian TH, Varrassi G, Paladini A, Vadalouka A, Zis P. Quality of life in painful peripheral neuropathies: a systematic review. Pain Res Manag. 2019;2019.
   PubMed Web of Science ®Google Scholar
• Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in T2DM. Diabetes Care. 2006;29(7):1518–1522. doi:10.2337/dc05-2228
   PubMed Web of Science ®Google Scholar
• Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes. Diabetologia. 2017;60(9):1586–1593. doi:10.1007/s00125-017-4336-x
   PubMed Web of Science ®Google Scholar
• Chen KK, Anderson RC. The toxicity and general pharmacology of N1-p-chlorophenyl-N5-isopropyl biguanide. J Pharmacol Exp Ther. 1947;91:157–160.
   PubMedGoogle Scholar
• Garcia E. 1949 flumamine. untraced publication from the Philippines. cited by Sterne J in an interview [April 4, 1996] for Merck-Lipha published in Glucophage. In: Pasik C, editor. Serving Diabetology for 40 Years. Lyon: GroupeLipha; 1997:21, 29.
   Google Scholar
• Sterne J. Innovations in antidiabetics. NN dimethylamine guanyl guanidine [N.N.D.G.]. Maroc Med. 1957;36:1295–1296.
   Google Scholar
• McCreight LJ, Stage TB, Connelly P, et al. Pharmacokinetics of metformin in patients with gastrointestinal intolerance. Diabetes Obes Metab. 2018;20(7):1593–1601. doi:10.1111/dom.13264
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Hiel S, Delzenne NM. Metformin: old friend, new ways of action–implication of the gut microbiome? Curr Opin Clin Nutr Metab Care. 2018;21(4):294–301. doi:10.1097/MCO.0000000000000468
   PubMedGoogle Scholar
• Rena G, Grahame HR, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60:1577–1585. doi:10.1007/s00125-017-4342-z
   PubMed Web of Science ®Google Scholar
• McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016;59:426–435. doi:10.1007/s00125-015-3844-9
   PubMed Web of Science ®Google Scholar
• Mehnert H, Seitz W. Further results of diabetes therapy with blood sugar lowering biguanides. Munch Med Wochenschr. 1958;100(47):1849–1851.
   PubMedGoogle Scholar
• Nattrass M, Alberti KG. Biguanides. Diabetologia. 1978;14:71–74. doi:10.1007/BF01263443
   PubMed Web of Science ®Google Scholar
• Hermann LS. Metformin: a review of its pharmacological properties and therapeutic use. Diabetes Metab. 1979;5:233–245.
   PubMed Web of Science ®Google Scholar
• Campbell IW, Howlett HC. Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis. Diabetes Metab Rev. 1995;11(Suppl 1):S57–S62. doi:10.1002/dmr.5610110509
   PubMedGoogle Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with T2DM (UKPDS 34). Lancet. 1998;352:854–865. doi:10.1016/S0140-6736(98)07037-8
   PubMed Web of Science ®Google Scholar
• Kothari S, Dhami-Shah H, Shah SR. Antidiabetic drugs and statins in nonalcoholic fatty liver disease. J Clin Exp Hepatol. 2019;9(6):723–730. doi:10.1016/j.jceh.2019.06.003
   PubMed Web of Science ®Google Scholar
• Zhou T, Xu X, Du M, Zhao T, Wang J. A preclinical overview of metformin for the treatment of T2DM. Biomed Pharmacother. 2018;106:1227–1235. doi:10.1016/j.biopha.2018.07.085
   PubMed Web of Science ®Google Scholar
• Zilov AV, Abdelaziz SI, AlShammary A, et al. Mechanisms of action of metformin with special reference to cardiovascular protection. Diabetes Metab Res Rev. 2019;35(7):e3173. doi:10.1002/dmrr.3173
   PubMed Web of Science ®Google Scholar
• Schuiveling M, Vazirpanah N, Radstake TR, Zimmermann M, Broen JC. Metformin, a new era for an old drug in the treatment of immune mediated disease? Curr Drug Targets. 2018;19(8):945–959. doi:10.2174/1389450118666170613081730
   PubMedGoogle Scholar
• Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28:2345–2351. doi:10.2337/diacare.28.10.2345
   PubMed Web of Science ®Google Scholar
• De Jager J, Kooy A, Lehert P, et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in T2DM mellitus: a randomized, placebo-controlled trial. J Intern Med. 2005;257:100–109. doi:10.1111/j.1365-2796.2004.01420.x
   PubMed Web of Science ®Google Scholar
• Hattori Y, Suzuki K, Hattori S, Kasai K. Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension. 2006;47(6):1183–1188. doi:10.1161/01.HYP.0000221429.94591.72
   PubMed Web of Science ®Google Scholar
• Chen HP, Shieh JJ, Chang CC, et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut. 2013;62(4):606–615. doi:10.1136/gutjnl-2011-301708
   PubMed Web of Science ®Google Scholar
• Yu H, Zhong X, Gao P, et al. The potential effect of metformin on cancer: an umbrella review. Front Endocrinol. 2019;10:617. doi:10.3389/fendo.2019.00617
   PubMed Web of Science ®Google Scholar
• Florez H, Luo J, Castillo-Florez S, et al. Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with T2DM. Postgrad Med. 2010;122:112–120. doi:10.3810/pgm.2010.03.2128
   PubMed Web of Science ®Google Scholar
• Bouchoucha M, Uzzan B, Cohen R. Metformin and digestive disorders. Diabetes Metab. 2011;37:90–96. doi:10.1016/j.diabet.2010.11.002
   PubMed Web of Science ®Google Scholar
• Squibb BM. Glucophage (metformin hydrochloride) package insert. Bristol-Myers Squibb Company. New York. 2009
   Google Scholar
• Valdes-Ramos R, Guadarrama-Lopez A, Martinez-Carrillo B, Benitez-Arciniega A, Donaji A. Vitamins and T2DM mellitus endocrine, metabolic & immune disorders. Drug Targets. 2015;15:54–63.
   Google Scholar
• Loubatieres AL, Loubatieres-Mariani Alric MM, Blayac R, Valette G. Effects of thiamine pyrophosphate and sodium dichloroacetate on the increase of lactate and insulin outputs induced by phenformin on the isolated and perfused rat pancreas. C R Seances Soc Biol Fil. 1977;171:155–160.
   PubMedGoogle Scholar
• Valette G, Ribes G, Rondot AM, Loubatieres-Mariani MM, Loubatieres AL. Effect of cocarboxylase on hyperlactatemia and hyperpyruvicemia induced by phenformin in dogs. C R Seances Soc Biol Fil. 1975;169(1):121–125.
   PubMedGoogle Scholar
• Valette G, Ribes G, Loubatieres-Mariani MM, Loubatieres AL. Consequences of the chronic administration of phenformine on the blood thiamine level in the dog. C R Seances Soc Biol Fil. 1975;169(1):1562–1567.
   PubMedGoogle Scholar
• Alston TA. Does metformin interfere with thiamine? Arch Int Med. 2003;163:983. doi:10.1001/archinte.163.8.983
   PubMedGoogle Scholar
• Calabrese AT, Coley KC, DaPos SV, Swanson D, Rao RH. Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. Arch Intern Med. 2002;162:434–437. doi:10.1001/archinte.162.4.434
   PubMedGoogle Scholar
• Al-Attas O, Al-Daghri N, Alokail M, et al. Metabolic benefits of six-month thiamine supplementation in patients with and without diabetes mellitus type 2. Clin Med Insights Endocrinol Diabetes. 2014;7:1. doi:10.4137/CMED.S13573
   PubMedGoogle Scholar
• Liang X, Chein H-C, Yee SW, et al. Metformin is a substrate and inhibitor of the human thiamine transporter, THTR-2 (SLC19A3). Mol Pharm. 2015;12:4301–4310. doi:10.1021/acs.molpharmaceut.5b00501
   PubMed Web of Science ®Google Scholar
• Vora B, Green EA, Khuri N, Ballgren F, Sirota M, Giacomini KM. Drug–nutrient interactions: discovering prescription drug inhibitors of the thiamine transporter ThTR-2 (SLC19A3). Am J Clin Nutr. 2020;111(1):110–121. doi:10.1093/ajcn/nqz255
   PubMed Web of Science ®Google Scholar
• Thornalley PJ, Babaei-Jadidi R, Al Ali H, et al. High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia. 2007;50(10):2164–2170. doi:10.1007/s00125-007-0771-4
   PubMedGoogle Scholar
• Nix WA, Zirwes R, Bangert V, et al. Vitamin B status in patients with type 2 diabetes mellitus with and without incipient nephropathy. Diabetes Res Clin Pract. 2015;107(1):157–165. doi:10.1016/j.diabres.2014.09.058
   PubMed Web of Science ®Google Scholar
• Berchtold P, Dahlqvist A, Gustafson A, Asp NG. Effects of a biguanide (metformin) on vitamin B12 and folic acid absorption and intestinal enzyme activities. Scand J Gastroenterol. 1971;6:751–754. doi:10.3109/00365527109179948
   PubMed Web of Science ®Google Scholar
• Malaguarnera G, Gagliano C, Salomone S, et al. Folate status in type 2 diabetic patients with and without retinopathy. Clin Ophthalmol. 2015;9:1437. doi:10.2147/OPTH.S77538
   PubMed Web of Science ®Google Scholar
• Wulffele MG, Kooy A, Lehert P, et al. Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in T2DM mellitus: a randomized, placebo-controlled trial. J Intern Med. 2003;254:455–463. doi:10.1046/j.1365-2796.2003.01213.x
   PubMed Web of Science ®Google Scholar
• Sahin M, Tutuncu NB, Ertugrul D, Tanaci N, Guvener ND. Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with T2DM mellitus. J Diabetes Complicat. 2017;21:118–123.
   Google Scholar
• Carlsen SM, Folling I, Grill V, et al. Metformin increases total homocysteine levels in non-diabetic male patients with coronary heart disease. Scand J Clin Lab Invest. 1997;57(6):521–527. doi:10.3109/00365519709084603
   PubMed Web of Science ®Google Scholar
• Carpentier JL, Bury J, Luyckx A, et al. Vitamin B12 and folic acid serum levels in diabetics under various therapeutic regimens. Diabetes Metab. 1976;2:187–190.
   Google Scholar
• Buysschaert M, Wallemacq PE, Dramais AS, Hermans MP. Hyperhomocysteinemia in T2DM. Diabetes Care. 2000;3233:1816–1822.
   Google Scholar
• Aarsand AK, Carlsen SM. Folate administration reduces circulating homocysteine levels in NIDDM patients on long-term metformin treatment. J Int Med. 1998;244:169–174. doi:10.1046/j.1365-2796.1998.00361.x
   PubMedGoogle Scholar
• Van Etten R, de Koning E, Verhaar M, Gaillard CA, Rabelink T. Impaired NO-dependent vasodilation in patients with Type II (non-insulin-dependent) diabetes mellitus is restored by acute administration of folate. Diabetologia. 2002;45(7):1004–1010. doi:10.1007/s00125-002-0862-1
   PubMed Web of Science ®Google Scholar
• MacKenzie KE, Wiltshire EJ, Gent R, Hirte C, Piotto L, Couper JJ. Folate and vitamin B6 rapidly normalize endothelial dysfunction in children with type 1 diabetes mellitus. Pediatrics. 2006;118(1):242–253. doi:10.1542/peds.2005-2143
   PubMed Web of Science ®Google Scholar
• Lind MV, Lauritzen L, Kristensen M, Ross AB, Eriksen JN. Effect of folate supplementation on insulin sensitivity and type 2 diabetes: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2019;109(1):29–42. doi:10.1093/ajcn/nqy234
   PubMed Web of Science ®Google Scholar
• Dziegielewska-Gesiak S, Fatyga E, Kasiarz G, Wilczynski T, Muc-Wierzgon M, Kokot T. Vitamins B12 and D deficiencies and macro-and microelement disturbances among diabetic elderly patients. J Biol Regul Homeost Agents. 2019;33(2):477–483.
   PubMedGoogle Scholar
• Laird EJ, O’Halloran AM, Carey D, O’Connor D, Kenny RA, Molloy AM. Voluntary fortification is ineffective to maintain the vitamin B 12 and folate status of older Irish adults: evidence from the Irish Longitudinal Study on Ageing (TILDA). Br J Nutr. 2018;120(1):111–120. doi:10.1017/S0007114518001356
   PubMed Web of Science ®Google Scholar
• Armbrecht U, Stockbrügger RW, Rode J, Menon GG. P.B. Cotton development of gastric dysplasia in pernicious anaemia: a clinical and endoscopic follow-up study of 80 patients. Gut. 1990;31:1105–1109. doi:10.1136/gut.31.10.1105
   PubMed Web of Science ®Google Scholar
• Reinstatler L, Qi YP, Williamson RS, Garn JV, Oakley GP Jr. Association of biochemical B12 deficiency with metformin therapy and vitamin B12 Supplements: the national health and nutrition examination survey, 1999–2006. Diabetes Care. 2012;35(2):327–333. doi:10.2337/dc11-1582
   PubMed Web of Science ®Google Scholar
• Kozyraki R, Cases O. Vitamin B12 absorption: mammalian physiology and acquired and inherited disorders. Biochimie. 2013;95(5):1002–1007. doi:10.1016/j.biochi.2012.11.004
   PubMed Web of Science ®Google Scholar
• Quadros EV. Advances in the understanding of cobalamin assimilation and metabolism. Br J Haematol. 2010;148(2):195–204. doi:10.1111/j.1365-2141.2009.07937.x
   PubMed Web of Science ®Google Scholar
• Bauman WA, Shaw S, Jayatilleke E, et al. Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care. 2000;23(9):1227–1231. doi:10.2337/diacare.23.9.1227
   PubMed Web of Science ®Google Scholar
• RZ T, CC S, MH C, et al. Risk factors of vitamin B12 deficiency in patients receiving metformin. Arch Intern Med. 2006;166:1975–1979. doi:10.1001/archinte.166.18.1975
   PubMedGoogle Scholar
• Pierce SA, Chung AH, Black KK. Evaluation of vitamin B12 monitoring in a veteran population on long-term, high-dose metformin therapy. Ann Pharmacother. 2012;46:1470–1476. doi:10.1345/aph.1R223
   PubMed Web of Science ®Google Scholar
• Kos E. To determine the effect of metformin on 25-hydroxyvitamin D [25(OH)D] and vitamin B12 levels in patients with T2DM mellitus. Endocr Pract. 2012;18:179–184. doi:10.4158/EP11009.OR
   PubMed Web of Science ®Google Scholar
• Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term metformin use and vitamin B12 deficiency in the diabetes prevention program outcomes study. J Clin Endocrinol Metab. 2016;101(4):1754–1761. doi:10.1210/jc.2015-3754
   PubMed Web of Science ®Google Scholar
• Alvarez M, Rincon O, Saavedra G, Moreno SM. Vitamin B12 deficiency and diabetic neuropathy in patients taking metformin: a cross-sectional study. Endocr Connect. 2019;8(10):1324–1329. doi:10.1530/EC-19-0382
   PubMed Web of Science ®Google Scholar
• Liu KW. Metformin-associated vitamin B12 deficiency in the elderly. Asian J Gerontol Geriatr. 2011;6:82–87.
   Google Scholar
• Bell DS. Metformin-induced vitamin B12 deficiency presenting as a peripheral neuropathy. South Med J. 2010;103(3):265–267. doi:10.1097/SMJ.0b013e3181ce0e4d
   PubMed Web of Science ®Google Scholar
• de Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with T2DM and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ. 2010;340:c2181. doi:10.1136/bmj.c2181
   PubMed Web of Science ®Google Scholar
• Haeusler S, Parry-Strong A, Krebs JD. The prevalence of low vitamin B12 status in people with type 2 diabetes receiving metformin therapy in New Zealand—a clinical audit. N Z Med J. 2014;127(1404):8–16.
   PubMedGoogle Scholar
• Nervo M, Lubini A, Raimundo FV, et al. Vitamin B12 in metformin-treated diabetic patients: a cross-sectional study in Brazil. Rev Assoc Med Bras. 2011;57(1):46–49. doi:10.1016/S0104-4230(11)70015-X
   PubMed Web of Science ®Google Scholar
• Elhadd T, Ponirakis G, Dabbous Z, Siddique M, Chinnaiyan S, Malik RA. Metformin use is not associated with B12 deficiency or neuropathy in patients with T2DM mellitus in Qatar. Front Endocrinol. 2018;9:248. doi:10.3389/fendo.2018.0024
   PubMedGoogle Scholar
• Chapman L, Darling L, Brown J. Association between metformin and vitamin B12deficiency in patients with T2DM: a systematic review and meta-analysis. Diabetes Metab. 2016;42:316–327. doi:10.1016/j.diabet.2016.03.008
   PubMed Web of Science ®Google Scholar
• Cassinadane AV, Ramaswamy R, Govindarajan R, Srinivasan AR. A genetic perspective of METFORMIN INDUCED VITAmin B12 deficiency in type 2 diabetes mellitus patients. As J Med Sci. 2018;9(1):11–14. doi:10.3126/ajms.v9i1.18723
   Google Scholar
• Welch GN, Loscalzo J, Epstein FH. Homocysteine and atherothrombosis. N Engl J Med. 1998;338(15):1042–1050. doi:10.1056/NEJM199804093381507
   PubMed Web of Science ®Google Scholar
• Wile DJ, Toth C. Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. Diabetes Care. 2010;33:156–161. doi:10.2337/dc09-0606
   PubMed Web of Science ®Google Scholar
• Berchtold P, Bolli P, Arbenz U, Keiser G. Disturbance of intestinal absorption following metformin therapy (observations on the mode of action of biguanides). Diabetologia. 1969;5:405–412. doi:10.1007/BF00427979
   PubMed Web of Science ®Google Scholar
• Scalabrino G, Veber D, Mutti E. New pathogenesis of the cobalamin-deficient neuropathy. Med Secoli. 2007;19:9–18.
   PubMedGoogle Scholar
• Solomon LR. Diabetes as a cause of clinically significant functional cobalamin deficiency. Diabetes Care. 2011;34:1077–1080. doi:10.2337/dc11-0009
   PubMedGoogle Scholar
• Saperstein DS, Wolfe GI, Gronseth GS, et al. Challenges in the identification of cobalamin deficiency polyneuropathy. Arch Neurol. 2003;60:1296–1301. doi:10.1001/archneur.60.9.1296
   PubMedGoogle Scholar
• England JD, Gronseth GS, Franklin G, et al. Practice parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology. 2009;72:177–184. doi:10.1212/01.wnl.0000336345.70511.0f
   PubMed Web of Science ®Google Scholar
• Satyanarayana A, Balakrishna N, Pitla S, et al. Status of B-vitamins and homocysteine in diabetic retinopathy: association with vitamin-B12 deficiency and hyperhomocysteinemia. PLoS One. 2011;6(11):e26747. doi:10.1371/journal.pone.0026747
   PubMed Web of Science ®Google Scholar
• Callaghan TS, Hadden DR, Tomkin GH. Megaloblastic anemia due to vitamin B12 malabsorption associated with longterm metformin treatment. Br Med J. 1980;280:1214–1215. doi:10.1136/bmj.280.6225.1214
   PubMedGoogle Scholar
• Andres E. Metformin-associated vitamin B12 deficiency (letter). Arch Intern Med. 2002;162(19):2251–2252. doi:10.1001/archinte.162.19.2251-a
   PubMedGoogle Scholar
• Langan RC, Goodbred AJ. Vitamin B12 deficiency: recognition and management. Am Fam Physician. 2017;96(6):384–389.
   PubMed Web of Science ®Google Scholar
• Mazokopakis E, Starakis I. Recommendations for diagnosis and management of metformin-induced vitamin B12 (Cbl) deficiency. Diabetes Res Clin Pract. 2012;97:359–367. doi:10.1016/j.diabres.2012.06.001
   PubMed Web of Science ®Google Scholar
• Boucher BJ. Inadequate vitamin D status: does it contribute to the disorders comprising syndrome ‘X’? Br J Nutr. 1998;79:315–327. doi:10.1079/BJN19980055
   PubMed Web of Science ®Google Scholar
• Wang H, Chen W, Li D, et al. Vitamin D and chronic diseases. Aging Dis. 2017;8(3):346–353. doi:10.14336/AD.2016.1021
   PubMed Web of Science ®Google Scholar
• Takiishi T, Gysemans C, Bouillon R, Mathieu C. Vitamin D and diabetes. Endocrinol Metab Clin N Am. 2010;39:419–446.
   PubMed Web of Science ®Google Scholar
• Sohl E, van Schoor NM, de Jongh RT, et al. The impact of medication on vitamin D status in older individuals. Eur J Endocrinol. 2012;166(3):477–485. doi:10.1530/EJE-11-0917
   PubMed Web of Science ®Google Scholar
• van Orten-luiten AC, Janse A, Dhonukshe-Rutten RA, Witkamp RF. Vitamin D deficiency as adverse drug reaction? A cross-sectional study in Dutch geriatric outpatients. Eur J Clin Pharmacol. 2016;72(5):605–614. doi:10.1007/s00228-016-2016-2
   PubMed Web of Science ®Google Scholar
• Out M, Top WM, Lehert P, Schalkwijk CA, Stehouwer CD, Kooy A. Long‐term treatment with metformin in type 2 diabetes and vitamin D levels: a post‐hoc analysis of a randomized placebo‐controlled trial. Diabetes Obes Metab. 2018;20(8):1951–1956.
   PubMedGoogle Scholar
• Hruby A, Meigs JB, O’Donnell CJ, Jacques PF, McKeown NM. Higher magnesium intake reduces risk of impaired glucose and insulin metabolism and progression from prediabetes to diabetes in middle-aged Americans. Diabetes Care. 2014;37:419–427. doi:10.2337/dc13-1397
   PubMed Web of Science ®Google Scholar
• Massy ZA, Drueke TB. Magnesium and outcomes in patients with chronic kidney disease: focus on vascular calcification, atherosclerosis and survival. Clin Kidney J. 2012;5:i52–i61. doi:10.1093/ndtplus/sfr167
   PubMedGoogle Scholar
• Pham PC, Pham PM, Pham PA, et al. Lower serum magnesium levels are associated with more rapid decline of renal function in patients with diabetes mellitus type 2. Clinical Nephrol. 2005;63:429–436.
   PubMed Web of Science ®Google Scholar
• Sales CH, Pedrosa LF, Lima JG, Lemos TM, Colli C. Influence of magnesium status and magnesium intake on the blood glucose control in patients with type 2 diabetes. Clin Nutr. 2011;30(3):359–364. doi:10.1016/j.clnu.2010.12.011
   PubMed Web of Science ®Google Scholar
• Song Y, He K, Levitan EB, Manson JE, Liu S. Effects of oral magnesium supplementation on glycaemic control in Type 2 diabetes: a meta‐analysis of randomized double‐blind controlled trials. Diabetic Med. 2006;23(10):1050–1056. doi:10.1111/j.1464-5491.2006.01852.x
   PubMedGoogle Scholar
• Kamat S, Morkar D, Madnani S. Serum Magnesium Levels in Type 2 Diabetes Mellitus and its Association with the Microvascular Complications. [Doctoral dissertation]. Belagavi, Karnataka: KLE University.
   Google Scholar
• Gommers LM, Hoenderop JG, Bindels RJ, de Baaij JH. Hypomagnesemia in T2DM: a vicious circle? Diabetes. 2016;65:3–13. doi:10.2337/db15-1028
   PubMed Web of Science ®Google Scholar
• Pham PV, Pham PM, Pham S, Miller J, Pham PT. Hypomagnesemia in patients with T2DM. Clin J Am Soc Nephrol. 2007;2:366–373. doi:10.2215/CJN.02960906
   PubMed Web of Science ®Google Scholar
• Mather HM, Nisbet JA, Burton GH, et al. Hypomagnesaemia in diabetes. Clinica Chimica Acta. 1979;95:235–242. doi:10.1016/0009-8981(79)90364-4
   PubMed Web of Science ®Google Scholar
• Doşa MD, Hangan L-T, Crauciuc E, Galeş C, Nechifor M. Influence of therapy with metformin on the concentration of certain divalent cations in patients with non-insulin-dependent diabetes mellitus. Biol Trace Elem Res. 2011;142(1):36–46. doi:10.1007/s12011-010-8751-9
   PubMedGoogle Scholar
• Villa A, Zanada P, Pellegrino A, Nucera G, Martinoli E, Boschiero A, Campanini F. Iatrogenic hypomagnesemia: an underestimated clinical problem. Ital J Med. 2015;9:287–289.
   Google Scholar
• Kurstjens S, de Baaij JH, Bouras H, Bindels RJ, Tack CJ, Hoenderop JG. Determinants of hypomagnesemia in patients with type 2 diabetes mellitus. Eur J Endocrinol. 2017;176:11–19. doi:10.1530/EJE-16-0517
   PubMed Web of Science ®Google Scholar
• Dignan K. Effects of Proton pump inhibitors and metformin on hypomagnesemia in veterans with and without diabetes. Diabetes. 2017;66:A610.
   Google Scholar
• van Orten-luiten AC, Janse A, Verspoor E, Brouwer-Brolsma EM, Witkamp RF. Drug use is associated with lower plasma magnesium levels in geriatric outpatients; possible clinical relevance. Clin Nutr. 2019;38(6):2668–2676. doi:10.1016/j.clnu.2018.11.018
   PubMedGoogle Scholar
• Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50:81–98. doi:10.2165/11534750-000000000-00000
   PubMed Web of Science ®Google Scholar
• Minami T, Nogami M, Ogawa W. Mechanisms of metformin action: in and out of the gut. J Diabetes Investig. 2018;4:701–702.
   Google Scholar
• Fillinger S, Boschi-Muller S, Azza S, Dervn E, Branlant G, Aymerich S. Two glyceraldehyde-3-phosphate dehydrogenases with opposite physiological roles in a nonphotosynthetic bacterium. J Biol Chem. 2000;275:14031–14037. doi:10.1074/jbc.275.19.14031
   PubMedGoogle Scholar
• Stolberg L, Rolfe R, Gitlin N, et al. d-Lactic acidosis due to abnormal gut flora: diagnosis and treatment of two cases. N Engl J Med. 1982;306:1344–1348. doi:10.1056/NEJM198206033062207
   PubMed Web of Science ®Google Scholar
• Hove H, Mortensen PB. Colonic lactate metabolism and d-lactic acidosis. Dig Dis Sci. 1995;40:320–330. doi:10.1007/BF02065417
   PubMed Web of Science ®Google Scholar
• Halperin ML, Kamel KS. D-lactic acidosis: turning sugar into acids in the gastrointestinal tract. Kidney Int. 1996;49:1–8. doi:10.1038/ki.1996.1
   PubMedGoogle Scholar
• Gennari FJ, Weise WJ. Acid-base disturbances in gastrointestinal disease. Clin J Am Soc Nephrol. 2008;3:1861–1868. doi:10.2215/CJN.02450508
   PubMedGoogle Scholar
• Burton JH, Johnson M, Johnson J, Hsia D, Greenway F, Heiman M. Addition of a gastrointestinal microbiome modulator to metformin improves metformin tolerance and fasting glucose levels. J Diabetes Sci Technol. 2015;9(4):808–814. doi:10.1177/1932296815577425
   PubMedGoogle Scholar
• Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55–60. doi:10.1038/nature11450
   PubMed Web of Science ®Google Scholar
• Forslund K, Hildebrand F, Nielsen T. Disentangling the effects of T2DM and metformin on the human gut microbiota. Nature. 2015;528(7581):262–266. doi:10.1038/nature15766
   PubMed Web of Science ®Google Scholar
• Sun L, Xie C, Wang G, et al. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat Med. 2018;12:1919–1929. doi:10.1038/s41591-018-0222-4
   Google Scholar
• Pascale A, Marchesi N, Govoni S, Coppola A, Gazzaruso C. The role of gut microbiota in obesity, diabetes mellitus, and effect of metformin: new insights into old diseases. Curr Opin Pharmacol. 2019;49:1–5. doi:10.1016/j.coph.2019.03.011
   PubMed Web of Science ®Google Scholar
• Allen RH, Stabler SP, Savage DG, Lindenbaum J. Metabolic abnormalities in cobalamin (vitamin B12) and folate deficiency. FASEB J. 1993;7:1344–1353. doi:10.1096/fasebj.7.14.7901104
   PubMed Web of Science ®Google Scholar
• Steiner I, Kidron D, Soffer D, Wirguin I, Abramsky O. Sensory peripheral neuropathy of vitamin B12 deficiency: a primary demyelinating disease? J Neurol. 1988;235:163–164. doi:10.1007/BF00314308
   PubMed Web of Science ®Google Scholar
• Misra UK, Kalita J, Das A. Vitamin B12 deficiency neurological syndromes: a clinical, MRI and electrodiagnostic study. Electromyogr Clin Neurophysiol. 2003;43:57–64.
   PubMedGoogle Scholar
• Kalita J, Chandra S, Bhoi SK, et al. Clinical, nerve conduction and nerve biopsy study in vitamin B12 deficiency neurological syndrome with a short-term follow-up. Nutr Neurosci. 2014;17(4):156–163. doi:10.1179/1476830513Y.0000000073
   PubMed Web of Science ®Google Scholar
• Singh R, Kishore L, Kaur N. Diabetic peripheral neuropathy: current perspective and future directions. Pharmacol Res. 2014;80:21–35. doi:10.1016/j.phrs.2013.12.005
   PubMed Web of Science ®Google Scholar
• Sun J, Wang Y, Zhang X, Zhu S, He H. Prevalence of peripheral neuropathy in patients with diabetes: a systematic review and meta-analysis. Prim Care Diabetes. 2020. S1751-9918(19)30284-0.
   Google Scholar
• Sadosky A, Mardekian J, Parsons B, et al. Healthcare utilization and costs in diabetes relative to the clinical spectrum of painful diabetic peripheral neuropathy. J Diabetes Complications. 2015;29(2):212–217. doi:10.1016/j.jdiacomp.2014.10.013
   PubMed Web of Science ®Google Scholar
• Pop-Busui R, Boulton A, Feldman E, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40:136–154. doi:10.2337/dc16-2042
   PubMed Web of Science ®Google Scholar
• Sun Y, Lai M-S, Lu C-J. Effectiveness of vitamin B12 on diabetic neuropathy: systematic review of clinical controlled trials. Acta Neurol Taiwan. 2005;14(2):48–54.
   PubMedGoogle Scholar
• Walker MJ Jr, Morris LM, Cheng D. Improvement of cutaneous sensitivity in diabetic peripheral neuropathy with combination L-methylfolate, methylcobalamin, and pyridoxal 5ʹ-phosphate. Rev Neurol Dis. 2010;7:132–139.
   PubMedGoogle Scholar
• Jacobs AM, Cheng D. Management of diabetic small-fiber neuropathy with combination L-methylfolate, methylcobalamin, and pyridoxal 5ʹ-phosphate. Rev Neurol Dis. 2011;8:39–47.
   PubMedGoogle Scholar
• Li G. Effect of mecobalamin on diabetic neuropathies: beijing methycobal Clinical Trial Collaborative Group. Zhonghua Nei Ke Za Zhi. 1999;38:14–17.
   PubMedGoogle Scholar
• Talaei A, Siavash M, Majidi H, Chehrei A. Vitamin B12 may be more effective than nortriptyline in improving painful diabetic neuropathy. Int J Food Sci Nutr. 2009;5:71–76. doi:10.1080/09637480802406153
   Google Scholar
• Farvid MS, Homayouni F, Amiri Z, Adelmanesh F. Improving neuropathy scores in type 2 diabetic patients using micronutrients supplementation. Diabetes Res Clin Pract. 2011;93:86–94. doi:10.1016/j.diabres.2011.03.016
   PubMed Web of Science ®Google Scholar
• Dominguez JC, Ng AR, Damian LF. A prospective, open label, 24-week trial of methylcobalamin in the treatment of diabetic polyneuropathy. J Diabetes Mellit. 2012;2:408–412.
   Google Scholar
• Tomkin GH, Hadden DR, Weaver JA, Montgomery DA. Vitamin B12 status of patients on long-term metformin therapy. BMJ. 1971;2:685–687. doi:10.1136/bmj.2.5763.685
   PubMed Web of Science ®Google Scholar
• Adams JF, Clark JS, Ireland JT, Kesson CM, Watson WS. Malabsorption of vitamin B12 and intrinsic factor secretion during biguanide therapy. Diabetologia. 1983;24(1):16–18. doi:10.1007/BF00275941
   PubMedGoogle Scholar
• Hermann L, Nilsson B, Wettre S. Vitamin B12 status of patients treated with metformin: a cross-sectional cohort study. Br J Diabetes Vasc Dis. 2004;4(6):401–406. doi:10.1177/14746514040040060701
   Google Scholar
• Pflipsen MC, Oh RC, Saguil A, Seehusen DA, Seaquist D, Topolski R. The prevalence of vitamin B(12) deficiency in patients with T2DM: a cross-sectional study. J Am Board Fam Med. 2009;22:528–534. doi:10.3122/jabfm.2009.05.090044
   PubMed Web of Science ®Google Scholar
• Qureshi SA, Ainsworth A, Winocour PH. Metformin therapy and assessment for vitamin B12 deficiency: is it necessary? Pract Diabetes. 2001;28:302–304.
   Google Scholar
• Calvo Romero JM, Ramiro Lozano JM. Vitamin B(12) in type 2 diabetic patients treated with metformin. Endocrinol Nutr. 2012;59:487–490. doi:10.1016/j.endonu.2012.06.005
   PubMedGoogle Scholar
• Sato Y, Ouchi K, Funase Y, Yamauchi K, Aizawa T. Relationship between metformin use, vitamin B12 deficiency, hyperhomocysteinemia and vascular complications in patients with T2DM. Endocr J. 2013;60:1275–1280. doi:10.1507/endocrj.EJ13-0332
   PubMed Web of Science ®Google Scholar
• Singh AK, Kumar A, Karmakar D, Jha RK. Association of B12 deficiency and clinical neuropathy with metformin use in T2DM patients. J Postgrad Med. 2013;59:253–257. doi:10.4103/0022-3859.123143
   PubMed Web of Science ®Google Scholar
• Kibirige D, Mwebaze R. Vitamin B12 deficiency among patients with diabetes mellitus: is routine screening and supplementation justified? J Diabetes Metab Disord. 2013;12(1):17.
   PubMedGoogle Scholar
• Caspary WF, Zavada I, Reimold W, Deuticke U, Emrich D, Willms B. Alteration of bile acid metabolism and vitamin B12 absorption in diabetics on biguanides. Diabetologia. 1977;13:187–193. doi:10.1007/BF01219698
   PubMed Web of Science ®Google Scholar
• Müller P, Fischer H, Sorger D. Vitamin B12 level in serum of diabetics receiving long-term buformin therapy. Z Gesamte Inn Med. 1981;36:226–228.
   PubMedGoogle Scholar
• Ahmed MA, Muntingh GL, Rheeder P. Perspectives on peripheral neuropathy as a consequence of metformin-induced vitamin B12 deficiency in T2DM. Intl J Endocrinol. 2017;2017:2452853. doi:10.1155/2017/2452853
   PubMed Web of Science ®Google Scholar
• Alharbi TJ, Tourkmani AM, Abdelhay O, et al. The association of metformin use with vitamin B12 deficiency and peripheral neuropathy in Saudi individuals with type 2 diabetes mellitus. PLoS One. 2018;13(10):e0204420.
   PubMed Web of Science ®Google Scholar
• Yang W, X L C, Wu H, Ji L. Associations between metformin use and vitamin B12 level, anemia and neuropathy in patients with diabetes: a meta-analysis. J Diabetes. 2019;11:729–743. doi:10.1111/1753-0407.12900
   PubMed Web of Science ®Google Scholar
• Wai WC, L C S, L C P, Cheng JN. Association of metformin use with vitamin B12 deficiency in the institutionalized elderly. Arch Geronto Geriatr. 2018;79:57–62.
   PubMedGoogle Scholar
• Gupta K, Jain A, Rohatgi A. An observational study of vitamin b12 levels and peripheral neuropathy profile in patients of diabetes mellitus on metformin therapy diabetes & metabolic syndrome. Clin Res Rev. 2018;12:51–58.
   Google Scholar
• Rodríguez-Gutiérrez R, Montes-Villarreal J, K R R-V, et al. Metformin use and vitamin B12 deficiency: untangling the association. Am J Med Sci. 2017;54:165–171.
   Google Scholar
• Devalia V, Hamilton MS, Molloy AM. British Committee for Standards in Haematology. Guidelines for the diagnosis and treatment of cobalamin and folate disorders. Br J Haematol. 2014;166(4):496–513. doi:10.1111/bjh.12959
   PubMed Web of Science ®Google Scholar
• de Groot-kamphuis DM, van Dijk PR, Groenier KH, Houweling ST, Bilo HJ, Kleefstra N. Vitamin B12 deficiency and the lack of its consequences in type 2 diabetes patients using metformin. Neth J Med. 2013;71:386–390.
   PubMed Web of Science ®Google Scholar
• Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143:199–211. doi:10.7326/0003-4819-143-3-200508020-00006
   PubMed Web of Science ®Google Scholar
• Friedenberg FK, Xanthopoulos M, Foster GD, Richter JE. The association between gastroesophageal reflux disease and obesity. Am J Gastroenterol. 2008;103:2111–2122. doi:10.1111/j.1572-0241.2008.01946.x
   PubMed Web of Science ®Google Scholar
• Lee SD, Keum B, Chun HJ, Bak YT. Gastroesophageal reflux disease in type II diabetes mellitus with or without peripheral neuropathy. J Neurogastroenterol Motil. 2011;17:274–278. doi:10.5056/jnm.2011.17.3.274
   PubMedGoogle Scholar
• Sun X-M, Tan J-C, Zhu Y, Lin L. Association between diabetes mellitus and gastroesophageal reflux disease: a meta-analysis. World J Gastroenterol. 2015;21:3085–3092. doi:10.3748/wjg.v21.i10.3085
   PubMed Web of Science ®Google Scholar
• Promberger R, Lenglinger J, Riedl O, et al. Gastro-esophageal reflux disease in type 2 diabetics: symptom load and pathophysiologic aspects: a retro-pro study. BMC Gastroenterol. 2013;13:132. doi:10.1186/1471-230X-13-132
   PubMedGoogle Scholar
• Lluch I, Ascaso JF, Mora F, et al. Gastroesophageal reflux in diabetes mellitus. Am J Gastroenterol. 1999;94:919–924. doi:10.1111/j.1572-0241.1999.987_j.x
   PubMed Web of Science ®Google Scholar
• Wang X, Pitchumoni CS, Chandrarana K, Shah N. Increased prevalence of symptoms of gastroesophageal reflux diseases in type 2 diabetics with neuropathy. World J Gastroenterol. 2008;14:709–712. doi:10.3748/wjg.14.709
   PubMedGoogle Scholar
• Nishida T, Tsuji S, Tsujii M, et al. Gastroesophageal reflux disease related to diabetes: analysis of 241 cases with T2DM mellitus. J Gastroenterol Hepatol. 2004;19:258–265. doi:10.1111/j.1440-1746.2003.03288.x
   PubMedGoogle Scholar
• Mitchell SL, Rockwood K. The association between antiulcer medication and initiation of cobalamin replacement in older persons. J Clin Epidemiol. 2001;54:531–534. doi:10.1016/S0895-4356(00)00340-1
   PubMed Web of Science ®Google Scholar
• RW F, Meeker AD, Cady PS, Culbertson VL, Force WS, Kelley CM. Ambulatory care increased vitamin B12 requirement associated with chronic acid suppression therapy. Ann Pharmacother. 2003;37:490–493. doi:10.1345/aph.1C037
   PubMedGoogle Scholar
• Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol. 2004;57:422–428. doi:10.1016/j.jclinepi.2003.08.015
   PubMed Web of Science ®Google Scholar
• DeVault KR, Talley NJ. Insights into the future of gastric acid suppression. Nat Rev Gastroenterol Hepatol. 2009;6:524–532. doi:10.1038/nrgastro.2009.125
   PubMed Web of Science ®Google Scholar
• Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;310:2435–2442. doi:10.1001/jama.2013.280490
   PubMed Web of Science ®Google Scholar
• Aymard JP, Aymard B, Netter P, Bannwarth B, Trechot P, Streiff F. Haematological adverse effects of histamine H2-receptor antagonists. Med Toxicol Adverse Drug Exp. 1988;3(6):430–448. doi:10.1007/BF03259895
   PubMedGoogle Scholar
• Ruscin JM, Page RL 2nd, Valuck RJ. Vitamin B(12) deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor. Ann Pharmacother. 2002;36:812–816. doi:10.1345/aph.10325
   PubMed Web of Science ®Google Scholar
• Kirch W, Hoensch H, Janisch HD. Interactions and non-interactions with ranitidine. Clin Pharmacokinet. 1984;9:493–510. doi:10.2165/00003088-198409060-00002
   PubMedGoogle Scholar
• Bélaïche J, Zittoun J, Marquet J, Nurit Y, Yvart J. Effect of ranitidine on secretion of gastric intrinsic factor and absorption of vitamin B12. Gastroenterol Clin Biol. 1983;7:381–384.
   PubMedGoogle Scholar
• Termanini B, Gibril F, Sutliff VE, Yu F, Venzon DJ, Jensen RT. Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. Am J Med. 1998;104:422–430. doi:10.1016/s0002-9343(98)00087-4
   PubMed Web of Science ®Google Scholar
• Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther. 2008;27:1110–1121. doi:10.1111/j.1365-2036.2008.03658.x
   PubMed Web of Science ®Google Scholar
• Dharmarajan TS, Kanagala MR, Murakonda P, Lebelt AS, Norkus EP. Do acid-lowering agents affect vitamin B12 status in older adults? J Am Med Dir Assoc. 2008;9:162–167. doi:10.1016/j.jamda.2007.10.004
   PubMed Web of Science ®Google Scholar
• Rozgony NR, Fang C, Kuczmarski MF, Bob H. Vitamin B(12) deficiency is linked with long-term use of proton pump inhibitors in institutionalized older adults: could a cyanocobalamin nasal spray be beneficial? J Nutr Elder. 2010;29:87–99. doi:10.1080/01639360903574734
   PubMedGoogle Scholar
• Sagar M, Janczewska I, Ljungdahl A, Bertilsson L, Seensalu R. Effect of CYP2C19 polymorphism on serum levels of vitamin B12 in patients on long-term omeprazole treatment. Aliment Pharmacol Ther. 1999;13:453–458. doi:10.1046/j.1365-2036.1999.00490.x
   PubMed Web of Science ®Google Scholar
• Festen HP. Intrinsic factor secretion and cobalamin absorption: physiology and pathophysiology in the gastrointestinal tract. Scand J Gastroenterol Suppl. 1991;188:1–7. doi:10.3109/00365529109111222
   PubMedGoogle Scholar
• Force RW, Nahata MC. Effect of histamine H2-receptor antagonists on vitamin B12 absorption. Ann Pharmacother. 1992;26:1283–1286. doi:10.1177/106002809202601018
   PubMedGoogle Scholar
• Steinberg WM, King CE, Toskes PP. Malabsorption of protein-bound cobalamin but not unbound cobalamin during cimetidine administration. Dig Dis Sci. 1980;25:188–191. doi:10.1007/BF01308137
   PubMed Web of Science ®Google Scholar
• Doogue MP. A safe and effective drug? N Z Med J. 2014;127(1404):6.
   PubMedGoogle Scholar
• Jung SB, Nagaraja V, Kapur A, Eslick GD. Association between vitamin B12 deficiency and long-term use of acid-lowering agents: a systematic review and meta-analysis. Intern Med J. 2015;45(4):409–416. doi:10.1111/imj.12697
   PubMed Web of Science ®Google Scholar
• Cotter PE, O’Keeffe ST. Use of proton pump inhibitors is not associated with vitamin B12 deficiency and in older hospital patients: a case control study. Eur Geriatr Med. 2011;2:253–255.
   Web of Science ®Google Scholar
• Islam M, Poly TN, Walther B, et al. Adverse outcomes of long term use of proton pump inhibitors: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2018;30:1395–1405. doi:10.1097/MEG.0000000000001198
   PubMed Web of Science ®Google Scholar
• Singh A, Cresci GA, Kirby DF. Proton pump inhibitors: risks and rewards and emerging consequences to the gut microbiome. Nutr Clin Prac. 2018;33:614–624.
   PubMedGoogle Scholar
• Imhann F, Vich Vila A, Bonder MJ, et al. The influence of proton pump inhibitors and other commonly used medication on the gut microbiota. Gut Microbes. 2017;4:351–358. doi:10.1080/19490976.2017.1284732
   Google Scholar
• Minalyan A, Gabrielyan L, Scott D, Jacobs J, Pisegna JR. The gastric and intestinal microbiome: role of proton pump inhibitors. Curr Gastroenterol Rep. 2017;19(8):42.
   PubMedGoogle Scholar
• Long AN, Atwell CL, Yoo W, Solomon SS. Vitamin B(12) deficiency associated with concomitant metformin and proton pump inhibitor use. Diabetes Care. 2012;35:e84.
   PubMedGoogle Scholar
• Mukhtar M, Sherry D, Keaver L, McHugh CM. Metformin use and its association with vitamin B12 deficiency. Irish J Med Sci. 2018;187(Suppl 5):S215–S216.
   PubMedGoogle Scholar
• Mulla K, Bradbury K. Metformin use and vitamin B12 deficiency. Presented at: society for endocrinology 19–21 Nov 2018 Glasgow, UK. Endocrin Abstr. 2018;59:P092.
   Google Scholar
• Parry-Strong A, Langdana F, Haeusler S, Weatherall M, Krebs J. Sublingual vitamin B12 compared to intramuscular injection in patients with type 2 diabetes treated with metformin: a randomised trial. N Z Med J. 2016;129:67–75.
   PubMed Web of Science ®Google Scholar
• W B S, F W H M M, Van Deventer S, Tytgat G. Normalization of plasma vitamin B12 concentration by intranasal hydroxocobalamin in vitamin B12–deficient patients. Gastroenterology. 1997;113:430–433. doi:10.1053/gast.1997.v113.pm9247460
   PubMedGoogle Scholar
• Kancherla V, Garn JV, Zakai NA, et al. Multivitamin use and serum vitamin B12 concentrations in older-adult metformin users in REGARDS, 2003–2007. PLoS One. 2016;11:8. doi:10.1371/journal.pone.0160802
   Google Scholar
• Mahajan R, Gupta K. Revisiting metformin: annual vitamin B12 supplementation may become mandatory with long-term metformin use. J Young Pharm. 2010;2(4):428–429. doi:10.4103/0975-1483.71621
   PubMedGoogle Scholar
• Wåhlén A, Haenni A, Johansson H-E. Do we need to measure vitamin B12 and magnesium in morbidly obese patients with type 2 diabetes mellitus? Diabetes Metab Syndr Obes. 2017;10:151–154. doi:10.2147/DMSO.S131340
   PubMed Web of Science ®Google Scholar
• Miller JW. Proton pump inhibitors, H2-receptor antagonists, metformin, and vitamin B-12 deficiency: clinical implications. Adv Nutr. 2018;9:S511–518S.
   PubMed Web of Science ®Google Scholar